Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26408
Title: | Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals | Authors: | Tournoy, Kurt G. THOMEER, Michiel Germonpre, Paul Derijcke, Sofie De Pauw, Rebecca Galdermans, Daniella Govaert, Karl Govaerts, Elke Schildermans, Rob Declercq, Isabelle De Brucker, Nele Pat, Karin Van Herreweghe, Rika Van Zandweghe, Luc Vanmaele, Luc Van Damme, Valerie Marien, Heidi De Craene, Sofie Fabry, Isabelle Alexander, Patrick Vercauter, Piet Demedts, Ingel |
Issue Date: | 2018 | Source: | LUNG CANCER, 115, p. 49-55 | Abstract: | Objectives: In patients with refractory or recurrent non-small-cell lung cancer (NSCLC) after first line chemotherapy, phase III trials showed superiority of nivolumab, an IgG4 programmed death-1 immune-checkpoint inhibitor antibody, over docetaxel. We evaluated case mix, effectiveness and safety of nivolumab upon implementation in general practice. Materials and methods: In 20 general hospitals, all consecutive NSCLC patients treated with nivolumab within the medical need program (inclusion period 12 months) in Flanders - Belgium were evaluated. Results: There were 267 patients, Eastem Cooperative Oncology Group (ECOG) score was 2 in 24% and 0-1 in 76%. In 48%, two or more systemic regimens were given before nivolumab. The median overall survival was 7.8 months (95% confidence interval (CI) 6.3-9.3). At one year, the overall survival rate was 36.5 +/- 0.34%. Median progression-free survival was 3.7 months (95% CI 2.9-4.5). An objective response was obtained in 23.2%. ECOG score 2 and presence of liver metastasis strongly correlated with worse survival (p < 0.00001). Treatment related adverse events grade 3 or 4 were reported in 21%, colitis (4%) and pneumonitis (7%) were most frequent. Conclusion: Upon implementation of nivolumab therapy in general hospitals, the case mix was characterized by a more heavily pretreated population with a substantial fraction of patients with ECOG score 2. The median overall survival is slightly inferior to what was published in the randomized phase III trials. An ECOG score 2 and the presence of liver metastasis correlated strongly with a worse survival. We report a high prevalence of serious adverse events. | Notes: | Tournoy, KG (reprint author), Onze Lieve Vrouw Ziekenhuis Aalst, Dept Resp Med Thorac Oncol, Bldg X-2,Moorselbaan 164, B-9300 Aalst, Belgium. kurt.tournoy@olvz-aalst.be | Keywords: | Non-small cell lung cancer; Nivolumab; Immunotherapy; Metastatic lung cancer | Document URI: | http://hdl.handle.net/1942/26408 | ISSN: | 0169-5002 | e-ISSN: | 1872-8332 | DOI: | 10.1016/j.lungcan.2017.11.008 | ISI #: | 000424181800008 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2019 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0169500217305652-main.pdf Restricted Access | Published version | 678.04 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
16
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
38
checked on Oct 13, 2024
Page view(s)
70
checked on Sep 7, 2022
Download(s)
52
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.